

Interstitial Lung Disease and Diabetes (02446627)

Dear Editor (WJD),

We sincerely appreciate the reviewer's and editorial office's comments on our article.

We are attaching the revised article and the response to the comments. Please let us know if there is anything else you need from us at this time.

Thank you for your time and consideration.

Sincerely,

Salim Surani

Venkat Rajasurya

Reviewer #1

"This is a minireview regarding diabetes and interstitial lung disease (ILD) with special emphasis on IPF. The review is concisely written and easy to follow. The topic is timely and clinically of interest. 1. Therapeutic strategy is of great interest. Effects of not only metformin, but also other anti-diabetic medications as well as lifestyle modification on ILD should be more precisely described. 2. The authors also should discuss effects of strict glycemic control on development and/or progression of ILD. 3. On the other hand, the association of DPP-4 inhibitors with ILD has been reported. This point also included and discussed."

Author's response:

We appreciate the reviewer's valuable comments. We have added two subtopics in our revised article to address the reviewer's comments: Other antidiabetic medications associated with ILD and Effect of blood sugar control and lifestyle changes.

Science editor's comments:

"The results of Bing search are eligible, but the CrossCheck detection showed a high similarity to published articles (total 6% and 5%). The authors need to rephrase the repeated sentences."

Author's response:

We appreciate the editor's valuable comments. We rephrased the sentences that showed some similarity on the CrossCheck. We are attaching the image in power point format.